Vanguard Personalized Indexing Management LLC Buys 14,002 Shares of Hologic, Inc. $HOLX

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Hologic, Inc. by 82.8% during the second quarter, acquiring an additional 14,002 shares, bringing its total holdings to 30,917 shares valued at approximately $2,015,000.
• Hologic reported a quarterly earnings per share (EPS) of $1.08, exceeding analysts' expectations of $1.05, with a revenue of $1.02 billion, reflecting a 1.2% year-over-year increase.
• Bloomberg analytics indicate a consensus rating of "Moderate Buy" for Hologic, with a target price averaging $80.15, showing confidence in the company's performance and potential growth.

Vanguard Personalized Indexing Management LLC lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 82.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,917 shares of the medical equipment provider's stock after purchasing an additional 14,002 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Hologic were worth $2,015,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HOLX. Victory Capital Management Inc. boosted its position in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares during the last quarter. Nuance Investments LLC boosted its holdings in Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock valued at $66,794,000 after acquiring an additional 931,920 shares during the last quarter. Redwood Wealth Management Group LLC acquired a new stake in Hologic in the first quarter worth about $3,534,000. Invesco Ltd. raised its holdings in Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after purchasing an additional 764,573 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Hologic during the 1st quarter valued at about $30,317,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

HOLX opened at $68.50 on Friday. The stock has a market cap of $15.24 billion, a P/E ratio of 28.42, a P/E/G ratio of 2.30 and a beta of 0.63. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $67.08 and a 200 day simple moving average of $63.45.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period in the previous year, the firm earned $1.06 earnings per share. The company's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of several analyst reports. Morgan Stanley lifted their price target on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and upped their target price for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Hologic in a research note on Wednesday, October 8th. Finally, Argus increased their target price on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.15.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.